Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia Source: Eur Respir J 2008; 31: 356-362 Year: 2008
Usefulness of serum procalcitonin levels in pulmonary tuberculosis Source: Eur Respir J 2011; 37: 371 Year: 2011
Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia Source: Eur Respir J 2005; 25: 688-692 Year: 2005
Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013
Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008
C-reactive protein and pulmonary tuberculosis: What correlation with disease severity Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Serum procalcitonin concentrations in children with pulmonary tuberculosis, tuberculous infection and lober pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 176s Year: 2003
The prognostic value of consecutive C-reactive protein measurements in community acquired pneumonia Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015
High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 488s Year: 2006
Value of serum procalcitonin levels in the differential diagnosis of pneumonia and pulmonary embolism Source: Annual Congress 2011 - Assessment of severity and predictors of outcomes in community-acquired pneumonia Year: 2011
Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013
Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia Source: Eur Respir J 2008; 32: 726-732 Year: 2008
Usefulness of serum anti-glycopeptidolipid core IgA antibody assay for the diagnosis of pulmonary infection of mycobacterium avium complex Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014
Serum albumin and probability of pleural effusion in patients with community-acquired pneumonia Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013
C-reactive protein in pulmonary TB Source: Annual Congress 2009 - Diagnostic advances in tuberculosis Year: 2009
Measurements usefulness of serum C-reactive protein for management of adult community-acquired pneumonia Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009
Role of markers C-Reactive Protein, Procalcitonin and TREM-1 in diagnosis of infection pleural effusion Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management Year: 2018
Usefulness of procalcitonin as a predictor for bacteremia and prognosis in severe sepsis Source: International Congress 2016 – Infections, sepsis, and pulmonary embolism Year: 2016
Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP) Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016